intepirdine intepirdine intepirdine (inn; developmental codes sb-742457, rvt-101) is a selective 5-ht6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. it was under development by glaxosmithkline for the treatment of alzheimer's disease and demonstrated some preliminary efficacy in phase ii clinical trials. gsk chose not to continue development and sold the rights to axovant sciences for $5 million in december 2014. intepirdineclinical dataother namessb-742457, rvt-101routes ofadministrationoralatc codenonelegal statuslegal status investigational/abandoned identifiers iupac name 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline cas number607742-69-8 ypubchem cid11256720chemspider9431746 nunii2iob2m82hykeggd10942chemblchembl1083390 ncomptox dashboard (epa)dtxsid30976249 echa infocard100.158.094 chemical and physical dataformulac19h19n3o2smolar mass353.44 g·mol−13d model (jsmol)interactive image smiles c3cnccn3c1cccc(c1nc4)cc4s(=o)(=o)c2ccccc2 inchi inchi=1s/c19h19n3o2s/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20h,9-12h2 nkey:jjzfwrohysmcmu-uhfffaoysa-n n ny (what is this?) (verify) results of a phase iii clinical trial for the treatment of alzheimer's disease were reported in september 2017. the trial showed no improvement over control group and axovant lost 70% of its value upon the announcement of the trial results. intepirdine also entered clinical trials for dementia with lewy bodies, also with negative results. consequently, axovant announced in 2018 that it has discontinued development of this drug.